Hormone replacement therapy (HRT) has long been a subject of interest in the medical community, especially in relation to its effects on Alzheimer’s disease. Recent data presented at the American Neurological Association Annual Meeting 2025 shed light on how the timing of HRT initiation can impact the risks associated with Alzheimer’s disease development. This meta-analysis, which delved into over 50 clinical trials and observational studies, was presented by Vaibhav, a student at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in India.
The use of estrogen therapy in managing menopausal symptoms such as hot flashes and sleep disturbances, as well as its potential benefits for heart health and bone preservation, has been well-documented. Early studies in the 1990s indicated a significant risk reduction of 30% to 45% associated with estrogen therapy. However, subsequent randomized controlled trials, including the Women’s Health Initiative Memory Study, presented conflicting results, showing potential harm instead.
To address this discrepancy, Vaibhav and his team conducted a comprehensive meta-analysis, aiming to explore the concept of a “critical window” for HRT initiation and considering both disease progression and biomarker data. The study encompassed a vast participant pool of 8,408,575 postmenopausal women, with varied ethnic backgrounds and ages ranging from their fifties to seventies.
Results from the meta-analysis revealed intriguing trends based on the timing of HRT initiation. Women who began hormone replacement therapy after the age of 65, particularly those using progestin, showed a 38% increased risk for Alzheimer’s disease. In contrast, those who commenced therapy around the onset of menopause experienced a 22% reduction in risk, with a further decrease to 32% for those starting within 5 years of menopause.
Moreover, midlife HRT was associated with reduced tau deposition, as evidenced by PET scans and cerebrospinal fluid analysis, and larger brain volumes, particularly in carriers of the apolipoprotein e4 gene. Conversely, late initiation of hormone replacement therapy correlated with increased brain atrophy and potentially higher tau levels, suggesting a less favorable outcome.
The study underscored the importance of estrogen in maintaining brain health post-menopause by aiding in communication between brain cells, reducing inflammation, and preventing damage that could contribute to Alzheimer’s disease. However, caution was advised due to the potential triggers for inflammation and vascular stress that estrogen supplementation might induce, especially when started long after menopause.
While the findings suggested a protective effect of early HRT initiation against Alzheimer’s disease risks, it was emphasized that HRT should not be recommended solely for this purpose. Rather, its use should be considered for managing menopausal symptoms in the early post-menopausal period, with potential brain benefits. Late initiation after the age of 65 was discouraged due to associated risks, urging a focus on established strategies for Alzheimer’s disease prevention like blood pressure control and regular exercise.
Vaibhav and colleagues stressed the importance of open communication between women and their healthcare providers regarding the duration of HRT use, advocating for discussions on discontinuation after a few years and avoiding initiation in the later stages of life to mitigate potential risks. The team plans to expand their research efforts in the future, aiming to conduct large-scale randomized controlled trials to further investigate this intriguing relationship between HRT timing and Alzheimer’s disease risks.
In conclusion, this study adds a nuanced perspective to the ongoing discourse surrounding hormone replacement therapy and its implications for Alzheimer’s disease. By highlighting the significance of timing in HRT initiation and its potential impact on disease risks, it provides valuable insights for both healthcare providers and women considering hormone therapy post-menopause.
- Early initiation of hormone replacement therapy post-menopause may reduce Alzheimer’s disease risks
- Late initiation of HRT, especially after the age of 65, may be associated with increased risks
- HRT should not be recommended solely for Alzheimer’s disease prevention but considered for managing menopausal symptoms
- Open communication with healthcare providers is crucial for discussing the duration and timing of hormone replacement therapy
Tags: clinical trials
Read more on healio.com